[go: up one dir, main page]

WO1997012614A1 - Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique - Google Patents

Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique Download PDF

Info

Publication number
WO1997012614A1
WO1997012614A1 PCT/EP1996/004327 EP9604327W WO9712614A1 WO 1997012614 A1 WO1997012614 A1 WO 1997012614A1 EP 9604327 W EP9604327 W EP 9604327W WO 9712614 A1 WO9712614 A1 WO 9712614A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
acid addition
propyl
treatment
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/004327
Other languages
German (de)
English (en)
Inventor
Michael Herschel
Richard Reichl
Volkmar HÄSELBARTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to AU72856/96A priority Critical patent/AU7285696A/en
Publication of WO1997012614A1 publication Critical patent/WO1997012614A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings

Definitions

  • the present invention relates to the inhalation application of 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, in particular its (-) - enantiomer, and its pharmacologically acceptable acid addition salts.
  • Parkinson's disease is usually treated by oral administration of drugs.
  • the inhalative application proposed according to the invention brings with it significant advantages for Parkinson's patients which improve their living conditions. Parkinson's disease is associated with a state of sedation in many patients.
  • the inhalation application of Pramipexole according to the invention leads to an exceptionally rapid rise in blood level values within a very short time (minutes), as a result of which the state of the inhibition of movement is quickly eliminated. When administered orally, it can take up to two hours until optimal blood levels are reached.
  • 2-Amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole can be used in the form of its acid addition salts in the form of aqueous or ethanolic solutions for the preparation of an aerosol for use in accordance with the invention.
  • the preferred acid addition salt is dihydrochloride.
  • Devices for generating a metered dose aerosol are known from the prior art for the treatment of asthma diseases.
  • a device as described in WO 91/14468 - Atomization Devices and Methods - is particularly preferred. is disclosed.
  • the advantage of the device described there is that the propellant gases usually required for metered dose mhaiers (MDI's) for producing the aerosol can be dispensed with
  • pramipexole can also be applied using a so-called powder inhaler, in which micronized particles in a range from 1 to 15, preferably 4 to 8, ⁇ m of the active ingredient are inhaled directly as a powder.
  • Nembutal 30 mg / kg IV
  • the active ingredient was administered by means of Respimat blood plasma level: inhalation 2 mg
  • the buffer substances, the active substance and sodium pyrosulfite are successively dissolved in boiled water and cooled with CO 2 gassing. Make up to the given volume with boiled water and filter without pyrogen.
  • the inhalation solution must be prepared and filled in darkened rooms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'administration par inhalation de pramipexoles.
PCT/EP1996/004327 1995-10-04 1996-10-04 Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique Ceased WO1997012614A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72856/96A AU7285696A (en) 1995-10-04 1996-10-04 Administration by inhalation of 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazol, in particular of its (-)enantiomer and its pharmacologically tolerable acid addition salts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19536916.5 1995-10-04
DE19536916A DE19536916A1 (de) 1995-10-04 1995-10-04 Inhalative Applikation von 2-Amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol, insbesondere seines (-)-Enantiomeren, sowie deren pharmakologisch verträgliche Säureadditionssalze

Publications (1)

Publication Number Publication Date
WO1997012614A1 true WO1997012614A1 (fr) 1997-04-10

Family

ID=7773972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/004327 Ceased WO1997012614A1 (fr) 1995-10-04 1996-10-04 Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique

Country Status (4)

Country Link
AU (1) AU7285696A (fr)
DE (1) DE19536916A1 (fr)
WO (1) WO1997012614A1 (fr)
ZA (1) ZA968315B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2839431A1 (de) * 1978-09-11 1980-03-20 Dolorgiet Arzneimittelfabrik Arzneimittel
EP0186087A1 (fr) * 1984-12-22 1986-07-02 Dr. Karl Thomae GmbH Tétrahydro-benzothiazoles, leur procédé de préparation et leur utilisation comme intermédiaires ou médicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2839431A1 (de) * 1978-09-11 1980-03-20 Dolorgiet Arzneimittelfabrik Arzneimittel
EP0186087A1 (fr) * 1984-12-22 1986-07-02 Dr. Karl Thomae GmbH Tétrahydro-benzothiazoles, leur procédé de préparation et leur utilisation comme intermédiaires ou médicaments

Also Published As

Publication number Publication date
ZA968315B (en) 1997-04-04
DE19536916A1 (de) 1997-04-10
AU7285696A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
EP1178832B1 (fr) Nouvelles compositions medicamenteuses a base de bromide de tiotropium et de salmeterol
DE69721766T2 (de) Neue arzneiformulierung
DE69526425T2 (de) Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
AT401615B (de) Verwendung von speziellen 5ht3-antagonisten zur herstellung von arzneimitteln
EP1121112B1 (fr) Concentre stable de formoterol
DE3876877T2 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE19542281C2 (de) Verwendung von Epinastin für die Behandlung der Migräne
DE60209511T2 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
DE69024672T2 (de) Sprays zur Behandlung von Infektionen des Tractus Respiratorius
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
EP0675717B1 (fr) Utilisation de 2-amino-6-a-propyl-amino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) comme medicament a effet antidepresseur
EP1526870A1 (fr) Nouvelle combinaison de glucocorticoides et d'inhibiteurs de pde-4 pour traiter des maladies des voies respiratoires, des maladies allergiques, de l'asthme et des maladies pulmonaires chroniques obstructives
EP2320878B1 (fr) Monoterpène pour le traitement de maladies des voies respiratoires, en particulier de maladies bronchopulmonaires
EP1594500B1 (fr) Traitement de maladies bacteriennes des organes respiratoires par application locale de fluoroquinolones
DE10205274A1 (de) Neue Arzneimittelkompositionen enthaltend neben Anticholinergika heterocyclische Verbindungen
DE19519056A1 (de) Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation
DE60315426T2 (de) Pharmazeutische zusammensetzung enthaltend einen pde4 oder pde3/4 inhibitor und eine histaminrezeptorantagonisten
DE69527713T2 (de) Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung
DE3527587A1 (de) Nasale zubereitungen
DE3852717T2 (de) Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie.
WO1997012614A1 (fr) Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique
AT396332B (de) Pharmazeutische zusammensetzung
DE202012005650U1 (de) Kombinationstherapeutikum für die Behandlung von Rhinitis
EP0417637A2 (fr) Utilisation des agonistes de l'autorécepteur de la dopamine dans le traitement de la toxicomanie
DE602004003955T2 (de) Nasale pharmazeutische zusammensetzung von piribedil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR BY CA CN CZ EE HU IL JP KR KZ LT LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase